Passive Prophylactic Administration with a Single Dose of Anti–Fel d 1 Monoclonal Antibodies REGN1908–1909 in Cat Allergen–induced Allergic Rhinitis: A Randomized, Double-Blind, Placebo-controlled Clinical Trial
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Abstract Rationale Sensitization to Fel d 1 (Felis domesticus allergen 1) contributes to persistent allergic rhinitis and asthma. Existing treatment options for cat allergy, including allergen immunotherapy, are only moderately effective, and allergen immunotherapy has limited use because of safety concerns. Objectives To explore the relationship among the pharmacokinetic, clinical, and immunological effects of anti–Fel d 1 monoclonal antibodies (REGN1908–1909) in patients after treatment. Methods Patients received REGN1908–1909 (n = 36) or a placebo (n = 37) in a phase 1b study. Fel d 1–induced basophil and IgE-facilitated allergen binding responses were evaluated at baseline and Days 8, 29, and 85. Cytokine and chemokine concentrations in nasal fluids were measured, and REGN1908–1909 inhibition of allergen–IgE binding in patient serum was evaluated. Measurements and Main Results Peak serum drug concentrations were concordant with maximal observed clinical response. The anti–Fel d 1 IgE/cat dander IgE ratio in pretreatment serum correlated with Total Nasal Symptom Score improvement. The allergen-neutralizing capacity of REGN1908–1909 was observed in serum and nasal fluid and was detected in an inhibition assay. Type 2 cytokines (IL-4, IL-5, and IL-13) and chemokines (CCL17/TARC, CCL5/RANTES [regulated upon activation, normal T-cell expressed and secreted]) in nasal fluid were inhibited in REGN1908–1909–treated patients compared with placebo (P < 0.05 for all); IL-13 and IL-5 concentrations correlated with Total Nasal Symptom Score improvement. Ex vivo assays demonstrated that REGN1908 and REGN1909 combined were more potent than each alone for inhibiting FcεRI- and FcεRII (CD23)–mediated allergic responses and subsequent T-cell activation. Conclusions A single, passive-dose administration of Fel d 1–neutralizing IgG antibodies improved nasal symptoms in cat-allergic patients and was underscored by suppression of FcεRI-, FcεRII-, and T-helper cell type 2–mediated allergic responses. Clinical trial registered with www.clinicaltrials.gov (NCT02127801)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Burden of allergic rhinitis: Results from the Pediatric Allergies in America survey
Meltzer, E. O., Blaiss, M. S., Derebery, M. J., Mahr, T. A., Gordon, B. R., Sheth, K. K., Simmons, A. L., Wingertzahn, M. A., & Boyle, J. M. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.05.013 · Cited by 553
Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement
Orengo, J. M., Radin, A. R., Kamat, V., Badithe, A., Ben, L. H., Bennett, B. L., Zhong, S., Birchard, D., Limnander, A., Rafique, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03636-8 · Cited by 237 · cited 8×
“Using Erk phosphorylation and CD63(1) upregulationasaproximal readoutofbasophil activation, we previously showed that REGN1908–1909 prevented greater IgE engagement than each individual antibody alone (23).”
BackgroundMethodInfluentialSelf-citationNasal Immunotherapy to Parietaria: Evidence of Reduction of Local Allergic Inflammation
Passalacqua, G., Albano, M., Ruffoni, S., Pronzato, C., Riccio, A. M., Di Berardino, L., Scordamaglia, A., & Canonica, G. W. (1995) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.152.2.7633693 · Cited by 74
Cited by
Allergen immunotherapy: past, present and future
Durham, S. R., & Shamji, M. H. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00786-1 · Cited by 413
Self-citationThe role of allergen‐specific IgE, IgG and IgA in allergic disease
Shamji, M. H., Valenta, R., Jardetzky, T., Verhasselt, V., Durham, S. R., Würtzen, P. A., & van Neerven, R. J. J. (2021) · Allergy · doi:10.1111/all.14908 · Cited by 336
Self-citationRiabova, K., Karsonova, A. V., van Hage, M., Käck, U., Konradsen, J. R., Grönlund, H., Fomina, D., Beltyukov, E., Glazkova, P. A., Semenov, D. Y., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23136984 · Cited by 21
“A second, more recent allergen-specific treatment approach was based on passive immunization with two Fel d 1-specific monoclonal IgG4 antibodies that block the binding of IgE to Fel d 1 in allergic patients [31,32].”
BackgroundRecombinant Hypoallergenic Cat Allergy Vaccines
Trifonova, D., Curin, M., Focke‐Tejkl, M., Liu, Z., Borochova, K., Gattinger, P., van Hage, M., Grönlund, H., Kiss, R., Huang, H., et al. (2025) · Allergy · doi:10.1111/all.16542 · Cited by 10
Devadoss, D., Surbaugh, K., Manevski, M., Wickramaratne, C., Chaput, D., Chung, A., de Leon, F., Chand, H. S., & Dhau, J. S. (2023) · Scientific Reports · doi:10.1038/s41598-023-38155-0 · Cited by 5
Metadata
- Authors
- Shamji, M. H., Singh, I., Layhadi, J. A., Ito, C., Karamani, A., Kouser, L., Sharif, H., Tang, J., Handijiev, S., Parkin, R. V., Durham, S. R., Kostic, A., Orengo, J. M., DeVeaux, M., Kamal, M., Stahl, N., Yancopoulos, G. D., Wang, C. Q., & Radin, A. R.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-07-01
- Volume
- 204
- Issue
- 1
- Pages
- 23-33
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W3134854404
- Cited by
- 74
- References
- 4
- FWCI
- 8.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.